asacol 800mg enterosolventní tableta
tillotts pharma gmbh, rheinfelden array - 9268 mesalazin - enterosolventní tableta - 800mg - mesalazin
asacol enema 4g rektální suspenze
tillotts pharma gmbh, rheinfelden array - 9268 mesalazin - rektální suspenze - 4g - mesalazin
milurit 100mg tableta
egis pharmaceuticals plc, budapešť array - 1750 alopurinol - tableta - 100mg - alopurinol
milurit 300mg tableta
egis pharmaceuticals plc, budapešť array - 1750 alopurinol - tableta - 300mg - alopurinol
salofalk 1000mg granule s prodlouženým uvolňováním
dr. falk pharma gmbh, freiburg array - 9268 mesalazin - granule s prodlouženým uvolňováním - 1000mg - mesalazin
salofalk 1500mg granule s prodlouženým uvolňováním
dr. falk pharma gmbh, freiburg array - 9268 mesalazin - granule s prodlouženým uvolňováním - 1500mg - mesalazin
salofalk 3000mg granule s prodlouženým uvolňováním
dr. falk pharma gmbh, freiburg array - 9268 mesalazin - granule s prodlouženým uvolňováním - 3000mg - mesalazin
salofalk 500mg granule s prodlouženým uvolňováním
dr. falk pharma gmbh, freiburg array - 9268 mesalazin - granule s prodlouženým uvolňováním - 500mg - mesalazin
xeljanz
pfizer europe ma eeig - tofacitinib - artritida, revmatoidní - imunosupresiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
cotrimoxazol al forte 800mg/160mg tableta
stada arzneimittel ag, bad vilbel array - 1395 sulfamethoxazol; 1490 trimethoprim - tableta - 800mg/160mg - sulfamethoxazol a trimethoprim